The share price dipped below $1 -- into penny stock territory -- but analysts are optimistic they'll recover.

Barclays made a list of 35 stocks with overweight ratings that it expects to benefit from strong earnings next year.

Sarepta's trial supports its drug's 'potentially differentiated profile' to treat Duchenne muscular dystrophy, the company said. The stock is higher.

Stocks moving in premarket trading Friday include Boeing, Micron, Pfizer, Sarepta and Moderna.

Sarepta shares lose half their value after a gene-therapy study seen as a shoo-in treatment for Duchenne muscular dystrophy produces disappointing results.

Cramer says buyers are betting science will beat the virus. Here are the companies that can light the way forward.

U.S. stocks are poised to again hit fresh record highs as optimism rises around the 'phase one' trade agreement between the United States and China; Boeing's Starliner returns to Earth; 'The Rise of Skywalker' makes $175.5 million at the weekend box office but still disappoints.

Shares soar after the biotech company receives fast-track approval for its injectable treatment for Duchenne muscular dystrophy.

The nine-month results showed improvements for three clinical trial participants with Limb-girdle muscular dystrophy.

"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.

The residential real estate market has stumbled, after soaring in the first 18 months of the covid pandemic.

SoftBank's Vision Fund lost nearly $22 billion in the latest quarter.